NICE approves trastuzumab for early stage breast cancerBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7555.1409-a (Published 15 June 2006) Cite this as: BMJ 2006;332:1409
- Susan Mayor
Trastuzumab (Herceptin) should be used to treat women with early stage HER2 positive breast cancer except where there are concerns about cardiac function, says draft guidance for England and Wales and separate guidance for Scotland published last week.
The draft guidance was published by the National Institute for Health and Clinical Excellence (NICE), the body that advises on use of treatments by the NHS, only two weeks after the drug was licensed for use in early breast cancer.
It recommends the drug as a treatment option for women with early stage HER2 positive breast cancer after surgery, chemotherapy (whether neoadjuvant or adjuvant), and radiotherapy (if applicable). Trastuzumab should be given at intervals of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial